Puma Biotechnology, Inc.

NasdaqGS:PBYI 주식 보고서

시가총액: US$126.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Puma Biotechnology 관리

관리 기준 확인 3/4

Puma Biotechnology's CEO는 Alan Auerbach, Sep2010 에 임명되었습니다 의 임기는 13.75 년입니다. 총 연간 보상은 $ 2.94M, 29.8% 로 구성됩니다. 29.8% 급여 및 70.2% 보너스(회사 주식 및 옵션 포함). 는 $ 21.15M 가치에 해당하는 회사 주식의 14.19% 직접 소유합니다. 21.15M. 경영진과 이사회의 평균 재임 기간은 각각 6 년과 7.6 년입니다.

주요 정보

Alan Auerbach

최고 경영자

US$2.9m

총 보상

CEO 급여 비율29.8%
CEO 임기14yrs
CEO 소유권14.1%
경영진 평균 재임 기간6.3yrs
이사회 평균 재임 기간7.8yrs

최근 관리 업데이트

Recent updates

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Sep 05
Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt

Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M

Aug 04

Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

Jun 04
Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?

CEO 보상 분석

Alan Auerbach 의 보수는 Puma Biotechnology 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

US$15m

Dec 31 2023US$3mUS$878k

US$22m

Sep 30 2023n/an/a

US$4m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

US$5m

Dec 31 2022US$3mUS$852k

US$2k

Sep 30 2022n/an/a

US$10m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$18mUS$827k

-US$29m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$4mUS$834k

-US$60m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$4mUS$780k

-US$76m

Sep 30 2019n/an/a

-US$95m

Jun 30 2019n/an/a

-US$92m

Mar 31 2019n/an/a

-US$99m

Dec 31 2018US$6mUS$757k

-US$114m

Sep 30 2018n/an/a

-US$147m

Jun 30 2018n/an/a

-US$210m

Mar 31 2018n/an/a

-US$243m

Dec 31 2017US$3mUS$733k

-US$292m

보상 대 시장: Alan 의 총 보상 ($USD 2.94M )은 US 시장( $USD 683.56K ).

보상과 수익: Alan 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Alan Auerbach (54 yo)

14yrs

테뉴어

US$2,944,748

보상

Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...

리더십 팀

이름위치테뉴어보상소유권
Alan Auerbach
Founder14yrsUS$2.94m14.05%
$ 17.8m
Maximo Nougues
CFO & Principal Accounting Officer5.8yrsUS$1.23m0.24%
$ 297.7k
Douglas Hunt
Chief Regulatory Affairs6.7yrsUS$1.02m0.19%
$ 239.4k
Jeffrey Ludwig
Chief Commercial Officer4.5yrsUS$1.38m0.17%
$ 209.9k
Mariann Ohanesian
Senior Director of Investor Relations12.8yrs데이터 없음데이터 없음
Bo Chao
Senior Vice President of Clinical Developmentless than a year데이터 없음데이터 없음

6.3yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: PBYI 의 관리팀은 노련하고 경험 (평균 재직 기간 6 년)입니다.

이사회 구성원

이름위치테뉴어보상소유권
Alan Auerbach
Founder12.9yrsUS$2.94m14.05%
$ 17.8m
Jay Moyes
Lead Independent Director12.4yrsUS$172.27k0.043%
$ 55.0k
Michael Miller
Independent Director6.6yrsUS$162.90k0.041%
$ 51.6k
Troy Wilson
Independent Director10.9yrsUS$172.27k0.0018%
$ 2.3k
Alessandra Cesano
Independent Director2.2yrsUS$152.27k0.055%
$ 69.7k
Adrian Senderowicz
Independent Director9.1yrsUS$164.77k0%
$ 0
Allison Dorval
Independent Director3.2yrsUS$154.77k0.067%
$ 85.1k
Brian Stuglik
Independent Director4.2yrsUS$161.65k0.10%
$ 126.6k

7.8yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: PBYI 의 이사회는 경험(평균 재직 기간 7.6 년)으로 간주됩니다.